Among immunotherapies for mesothelioma, immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein (CTLA-4) have demonstrated the most promise. Here, CD274 is linked to mesothelioma.